Table 2.
Treatment.
| pCTX + TACE (n = 14) | n † | pCTX (n = 59) | n † | p Value | |
|---|---|---|---|---|---|
| Vital status—no. (%) | |||||
| alive | 3 (21.4) | 14 | 7 (11.9) | 59 | 0.392 |
| dead | 11 (78.6) | 52 (88.1) | |||
| alive-receiving pCTX treatment | 1 (7.1) | 14 | 3 (5.1) | 59 | 1.000 |
| Adjuvant CTX—no. (%) | |||||
| yes | 0 (0.0) | 14 | 8 (13.6) | 59 | 0.340 |
| pCTX lines—no. (%) | |||||
| 1 | 4 (28.6) | 14 | 23 (39.0) | 59 | 0.380 |
| 2 | 4 (28.6) | 24 (40.7) | |||
| 3 | 4 (28.6) | 7 (11.9) | |||
| 4 | 2 (14.3) | 4 (6.8) | |||
| 5 | 0 (0.0) | 1 (1.7) | |||
| median (range) | 2 (1–4) | 2 (1–5) | |||
| First-line pCTX—no. (%) | |||||
| Gemcitabine | 1 (7.1) | 14 | 13 (22.0) | 59 | 0.672 |
| GemCis/GemOx | 9 (64.3) | 25 (42.4) | |||
| FOLFOX/CAPOX | 1 (7.1) | 7 (11.9) | |||
| FOLFIRINOX | 1 (7.1) | 5 (8.5) | |||
| Other | 2 (14.3) | 9 (15.3) | |||
| Cycles (median (range)) | 6 (2–18) | 14 | 4 (1–27) | 59 | 0.200 |
| Second-line pCTX—no. (%) | |||||
| Gemcitabine | 2 (20.0) | 10 | 7 (19.4) | 36 | 0.563 |
| GemCis/GemOx | 2 (20.0) | 8 (22.2) | |||
| FOLFOX/CAPOX | 1 (10.0) | 11 (30.6) | |||
| FOLFIRINOX | 0 (0.0) | 1 (2.8) | |||
| Other | 5 (50.0) | 9 (25.0) | |||
| Cycles (median (range)) | 5 (1–11) | 10 | 4 (1–16) | 36 | 0.293 |
| Time surgery to recurrence—months | |||||
| median (range) | 8.3 (1.9–13.3) | 4 | 8.6 (0.2–42.5) | 24 | 0.550 |
| Time recurrence to last follow-up/death—months | |||||
| median (range) | 22.5 (18.0–44.4) | 4 | 14.5 (1.6–79.3) | 24 | 0.341 |
† no. of patients with available data. pCTX: palliative chemotherapy.